Abstract Details

Title Longitudinal study of symptom botheration in Multiple Sclerosis patients

Topic Multiple Sclerosis

Presentation(s) S26 - MS and CNS Inflammatory Disease: Clinical Considerations II (2:28 PM-2:39 PM)

Poster/Presentation
Number 009

Objective 1. To report on longitudinal changes in symptoMScreen scores in MS patients followed in two large, multi-ethnic MS centers; 2. To investigate the relationship between changes in symptoMScreen and disability scores.

Background Little is known about longitudinal changes in symptom impact in MS patients. SymptoMScreen is a validated, patient-reported outcome measure for assessing symptom severity in 12 domains commonly affected by MS: walking, dexterity, spasticity, bodily pain, sensory, bladder, fatigue, vision, dizziness, cognitive, depression and anxiety (Green et al, 2016).

Design/Methods SymptoMScreen and disability score (Patient-Determined Disability Steps, PDDS) were collected on consecutive MS patients attending NYU (New York City, NY) and Barnabas (Livingston, NJ) MS Centers. We retroactively analyzed responses in all MS patients, who fully completed 2 SymptoMScreen and PDDS questionnaires over a period of 12 months or more.

Results 594 MS patients satisfied the inclusion criteria. Mean age was 44.4 (12.3); disease duration - 11.3 (9.1); 72.6% were female and 39.6% were non-White. Follow-up period was 16.7 (3.7) months. Mean total SymptoMScreen score increased from 17.3 at baseline to 18.1 at the last follow-up (paired t-test, p=0.03). Among SymptoMScreen subscores, significant increases were seen only in bladder (p<0.001), hand (p=0.04) and dizziness (p=0.05) domains. Mean (PDDS) increased from 1.8 at baseline to 2.0 at the last follow-up (p>0.05). In a multivariable ordinal regression model with change in PDDS as an outcome variable and age, sex, race and symptoMScreen change as predictor variables, only symptoMScreen change was a predictor of change in PDDS (correlation coefficient of 0.28).

Conclusions Overall symptoms botheration, as assessed with SymptoMScore, has increased slightly but significantly over a period of ~17 months, driven mainly by increases in bladder, dexterity and dizziness domains. Disability (PDDS) increased non-significantly. Change in symptoMScore was the only significant predictor of change in disability score in the multivariate model.

Authors/Disclosures
Ilya Kister, MD, FAAN (NYU School of Medicine) PRESENTER	Dr. Kister has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech-Roche. Dr. Kister has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. The institution of Dr. Kister has received research support from Genentech. The institution of Dr. Kister has received research support from Novartis. Dr. Kister has received publishing royalties from a publication relating to health care.
Tamar Bacon	The institution of an immediate family member of Tamar Bacon has received research support from Novartis. The institution of an immediate family member of Tamar Bacon has received research support from Genentech. An immediate family member of Tamar Bacon has received publishing royalties from a publication relating to health care.
	No disclosure on file
Gary R. Cutter, PhD (University of Alabama At Birmingham)	Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for onsulting or Advisory Boards: Alexion, Antisense Therapeutics/Percheron, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions LLC, Endra Life Sciences, Cognito Therapeutics, Genzyme, Genentech, Immunic, Klein-Buendel Incorporated, Kyverna Therapeutics, Inc. , Linical, Merck/Serono, Noema, Neurogenesis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Revelstone Consulting, Roche, SAB Biotherapeutics, Sapience Therapeutics, Scott&Scott LLP, Tenmile.. Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Data and Safety Monitoring Boards: Applied Therapeutics, AI therapeutics, AMO Pharma, Argenx, Astra-Zeneca, Avexis Pharmaceuticals, Bristol Meyers Squibb, CSL Behring, Cynata Therapeutics, DiamedicaTherapeutics, Horizon Pharmaceuticals, Immunic, Inhibrix, Karuna Therapeutics, Kezar Life Sciences, Medtronic, Merck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma Holdings, Prothena Biosciences, Novartis, Pipeline Therapeutics (Contineum), Regeneron, Sanofi-Aventis, Teva Pharmaceuticals, United BioSource LLC, University of Texas Southwestern.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN.

��ɫ��

��ɫ��